Onconetix Inc. announces successful Proclarix® clinical study results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2025
0mins
Should l Buy ONCO?
Source: Newsfilter
Onconetix Inc. shares rose by 5.06% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment.
The recent clinical study results for Proclarix® demonstrated its superior performance in reducing the overdiagnosis of clinically insignificant prostate cancer, significantly lowering unnecessary biopsies. Additionally, the initiation of the PRIME multi-center clinical validation study in collaboration with Labcorp aims to evaluate Proclarix® in the U.S. market, further enhancing its commercial potential.
These developments not only reinforce the clinical utility of Proclarix® but also position Onconetix Inc. favorably in the market, potentially leading to increased adoption and revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONCO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONCO
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Proclarix® Clinical Data Reinforces Performance in Reducing Overdiagnosis
- Clinical Study Results: A clinical study conducted in Denmark demonstrated Proclarix®'s superior performance in a cohort of 371 men, significantly reducing the misdiagnosis of clinically insignificant prostate cancer and unnecessary biopsies, showcasing its effectiveness in early identification of clinically significant prostate cancer.
- New Research Publications: Two new peer-reviewed papers further validate the clinical utility of Proclarix®, with the first paper showing its superiority in reducing misdiagnosis and biopsy risks compared to %fPSA and the ERSPC risk calculator, while the second paper emphasizes its prognostic value in predicting patient transitions from active surveillance to treatment.
- PRIME Study Initiation: PMX has launched the PRIME multi-center clinical validation study in collaboration with Labcorp to evaluate Proclarix® in the U.S. market, aiming to enroll up to 500 male participants to ensure broad applicability and effectiveness of the findings.
- European Market Expansion: PMX continued to enhance its commercial presence in Europe during Q1 2026, particularly in the UK, where Proclarix® was included in a patient organization’s early screening initiative, with nearly 100 tests conducted in the first quarter, indicating growing market demand.
See More
REPL Faces Pressure After FDA Issues Second Complete Response Letter
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
See More
Onconetix Appoints New CEO and Board Member
- New CEO Appointment: Onconetix announced the appointment of David White as CEO effective March 18, 2026, bringing over 30 years of executive leadership experience across various sectors, which is expected to drive strategic transformation within the company.
- Board Member Addition: Sammy Dorf has been appointed to the Board of Directors and the audit committee effective March 19, 2026; as a co-founder of Verano Holdings, his experience is anticipated to enhance the company's governance capabilities.
- Interim CFO Continuity: The outgoing interim CEO, Karina Fedasz, will continue to serve as interim CFO, ensuring financial stability during the transition period, which reflects the company's commitment to management continuity.
- Stock Price Decline: Onconetix shares fell by 19.07%, indicating market caution regarding the leadership changes, which may impact investor confidence and exert pressure on the company's future growth prospects.
See More
What’s Behind the 50% Surge of This Micro-Cap Stock in Premarket Trading?
Merger Announcement: Onconetix is in the process of merging with Realbotix, a robotics company, which is expected to enhance its business focus on AI-powered humanoid robotics.
Stock Surge: Shares of Onconetix surged by 50% in pre-market trading following a 1-for-5 reverse stock split and news of the merger, indicating positive market sentiment.
Acquisition Details: The merger will give Realbotix's parent company a majority stake of up to 90% in the combined entity, with the deal expected to close in the second half of 2026.
Market Performance: Despite the surge, Onconetix shares have declined nearly 60% year-to-date, with retail sentiment remaining neutral as trading volumes increased significantly.
See More
Onconetix Partners with Realbotix for 6G Trial
- 6G Trial Participation: Onconetix (ONCO) announced Realbotix's involvement in Ericsson's world-first 6G over-the-air trial at its U.S. headquarters in Plano, Texas, marking Realbotix as Ericsson's first enterprise robotics client.
- Real-Time Interaction Showcase: During the trial, the Realbotix robot transmitted video and interacted in real-time over Ericsson's test network, demonstrating how next-generation wireless networks can support AI robotics and real-time video streaming, highlighting the high-speed, low-latency connectivity essential for future AI-driven technologies.
- AI-Agnostic Architecture: The demonstration underscored Realbotix's AI-agnostic architecture, allowing its humanoid robots to integrate with multiple AI systems, cloud platforms, and network environments, designed to enable operation across diverse ecosystems without reliance on a single AI provider.
- Acquisition Agreement Progress: Onconetix previously announced a definitive agreement to acquire Realbotix LLC in an all-stock transaction, with the combined company expected to trade on Nasdaq in the second half of 2026, subject to shareholder and regulatory approvals, indicating a strategic move in the robotics sector.
See More
Onconetix Announces 1-for-5 Reverse Stock Split
- Reverse Stock Split Announcement: Onconetix has announced a 1-for-5 reverse stock split effective March 25, 2026, aimed at reducing the number of outstanding shares to comply with Nasdaq's minimum bid price requirement of $1.00 per share.
- Outstanding Shares Reduction: The reverse split will decrease the company's outstanding shares from approximately 3.6 million to about 0.7 million, significantly lowering the share count in the market, which may help elevate the stock price to meet Nasdaq's listing standards.
- Market Reaction: Following the announcement, Onconetix's stock price fell by 16.12% in premarket trading to $0.52, indicating a negative market response that could undermine investor confidence in the company's future prospects.
- Listing Compliance Pressure: The implementation of the reverse stock split highlights the ongoing pressure the company faces to maintain its Nasdaq listing, suggesting a need for further strategic adjustments to improve its financial performance.
See More
Proclarix® Clinical Data Reinforces Performance in Reducing Overdiagnosis
- Clinical Study Results: A clinical study conducted in Denmark demonstrated Proclarix®'s superior performance in a cohort of 371 men, significantly reducing the misdiagnosis of clinically insignificant prostate cancer and unnecessary biopsies, showcasing its effectiveness in early identification of clinically significant prostate cancer.
- New Research Publications: Two new peer-reviewed papers further validate the clinical utility of Proclarix®, with the first paper showing its superiority in reducing misdiagnosis and biopsy risks compared to %fPSA and the ERSPC risk calculator, while the second paper emphasizes its prognostic value in predicting patient transitions from active surveillance to treatment.
- PRIME Study Initiation: PMX has launched the PRIME multi-center clinical validation study in collaboration with Labcorp to evaluate Proclarix® in the U.S. market, aiming to enroll up to 500 male participants to ensure broad applicability and effectiveness of the findings.
- European Market Expansion: PMX continued to enhance its commercial presence in Europe during Q1 2026, particularly in the UK, where Proclarix® was included in a patient organization’s early screening initiative, with nearly 100 tests conducted in the first quarter, indicating growing market demand.
See More
REPL Faces Pressure After FDA Issues Second Complete Response Letter
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
See More
Onconetix Appoints New CEO and Board Member
- New CEO Appointment: Onconetix announced the appointment of David White as CEO effective March 18, 2026, bringing over 30 years of executive leadership experience across various sectors, which is expected to drive strategic transformation within the company.
- Board Member Addition: Sammy Dorf has been appointed to the Board of Directors and the audit committee effective March 19, 2026; as a co-founder of Verano Holdings, his experience is anticipated to enhance the company's governance capabilities.
- Interim CFO Continuity: The outgoing interim CEO, Karina Fedasz, will continue to serve as interim CFO, ensuring financial stability during the transition period, which reflects the company's commitment to management continuity.
- Stock Price Decline: Onconetix shares fell by 19.07%, indicating market caution regarding the leadership changes, which may impact investor confidence and exert pressure on the company's future growth prospects.
See More
What’s Behind the 50% Surge of This Micro-Cap Stock in Premarket Trading?
Merger Announcement: Onconetix is in the process of merging with Realbotix, a robotics company, which is expected to enhance its business focus on AI-powered humanoid robotics.
Stock Surge: Shares of Onconetix surged by 50% in pre-market trading following a 1-for-5 reverse stock split and news of the merger, indicating positive market sentiment.
Acquisition Details: The merger will give Realbotix's parent company a majority stake of up to 90% in the combined entity, with the deal expected to close in the second half of 2026.
Market Performance: Despite the surge, Onconetix shares have declined nearly 60% year-to-date, with retail sentiment remaining neutral as trading volumes increased significantly.
See More
Onconetix Partners with Realbotix for 6G Trial
- 6G Trial Participation: Onconetix (ONCO) announced Realbotix's involvement in Ericsson's world-first 6G over-the-air trial at its U.S. headquarters in Plano, Texas, marking Realbotix as Ericsson's first enterprise robotics client.
- Real-Time Interaction Showcase: During the trial, the Realbotix robot transmitted video and interacted in real-time over Ericsson's test network, demonstrating how next-generation wireless networks can support AI robotics and real-time video streaming, highlighting the high-speed, low-latency connectivity essential for future AI-driven technologies.
- AI-Agnostic Architecture: The demonstration underscored Realbotix's AI-agnostic architecture, allowing its humanoid robots to integrate with multiple AI systems, cloud platforms, and network environments, designed to enable operation across diverse ecosystems without reliance on a single AI provider.
- Acquisition Agreement Progress: Onconetix previously announced a definitive agreement to acquire Realbotix LLC in an all-stock transaction, with the combined company expected to trade on Nasdaq in the second half of 2026, subject to shareholder and regulatory approvals, indicating a strategic move in the robotics sector.
See More
Onconetix Announces 1-for-5 Reverse Stock Split
- Reverse Stock Split Announcement: Onconetix has announced a 1-for-5 reverse stock split effective March 25, 2026, aimed at reducing the number of outstanding shares to comply with Nasdaq's minimum bid price requirement of $1.00 per share.
- Outstanding Shares Reduction: The reverse split will decrease the company's outstanding shares from approximately 3.6 million to about 0.7 million, significantly lowering the share count in the market, which may help elevate the stock price to meet Nasdaq's listing standards.
- Market Reaction: Following the announcement, Onconetix's stock price fell by 16.12% in premarket trading to $0.52, indicating a negative market response that could undermine investor confidence in the company's future prospects.
- Listing Compliance Pressure: The implementation of the reverse stock split highlights the ongoing pressure the company faces to maintain its Nasdaq listing, suggesting a need for further strategic adjustments to improve its financial performance.
See More
